NIASPAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Niaspan, and when can generic versions of Niaspan launch?
Niaspan is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in NIASPAN is niacin. There are fourteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the niacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Niaspan
A generic version of NIASPAN was approved as niacin by BARR on April 14th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NIASPAN?
- What are the global sales for NIASPAN?
- What is Average Wholesale Price for NIASPAN?
Summary for NIASPAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 212 |
| Clinical Trials: | 45 |
| Patent Applications: | 4,069 |
| Drug Prices: | Drug price information for NIASPAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NIASPAN |
| What excipients (inactive ingredients) are in NIASPAN? | NIASPAN excipients list |
| DailyMed Link: | NIASPAN at DailyMed |
Recent Clinical Trials for NIASPAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pharmena North America | Phase 1 |
| Cortria Corporation | Phase 1 |
| PPD | Phase 1 |
US Patents and Regulatory Information for NIASPAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-004 | Jul 28, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-003 | Jul 28, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-001 | Jul 28, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-002 | Jul 28, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | NIASPAN TITRATION STARTER PACK | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-005 | Jul 28, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NIASPAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-001 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-003 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-002 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-002 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-004 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-004 | Jul 28, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NIASPAN
See the table below for patents covering NIASPAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Brazil | 9815454 | ⤷ Sign Up | |
| Finland | 991895 | ⤷ Sign Up | |
| Norway | 20000406 | ⤷ Sign Up | |
| Canada | 2283322 | KIT DE DEPART CONTENANT DES COMPOSITIONS D'ACIDE NICOTINIQUE (STARTER KIT CONTAINING NICOTINIC ACID COMPOSITIONS) | ⤷ Sign Up |
| Canada | 2591710 | ⤷ Sign Up | |
| Finland | 19991895 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
